News

Inside Opus One, Where Chef-Driven Pairings Meet Iconic Napa Wine

Opus One may be known for its Bordeaux-style blend, but under Chef Sean Koenig the winery’s culinary program is showing how ...
Lifewire on MSN1d

Claude Gets the Power to Walk Away

President Donald Trump has taken aim at MSNBC host Nicolle Wallace in a bizarre social media rant. The drama started when ...

Claude Code Opus Plan Mode With 1 Million Context Window Tested

From multi-step plans to book-length context, learn how Claude Code Opus helps you eliminate inefficiency and unlock new AI ...

Why Anthropic is letting Claude walk away from you — but only in 'extreme cases'

Claude won't stick around for toxic convos. Anthropic says its AI can now end extreme chats when users push too far.
Ophthalmology Times1d

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

Anthropic's Claude AI now has the ability to end 'distressing' conversations

A new feature with Claude Opus 4 and 4.1 lets it end conversations with users with "persistently harmful or abusive ...
TipRanks on MSN2d

Opus Genetics announces FDA clearance of IND application for OPGx-BEST1

Opus Genetics (IRD) announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug, IND, application for ...

Claude AI Can Now End 'Harmful' Conversations

Anthropic has given its chatbot, Claude, the ability to end conversations it deems harmful. You likely won't encounter the ...

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical ...